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Clostridium perfringens enterotoxin (CPE) causes the symptoms associated with several common gastrointestinal diseases. CPE
is a 35kDa polypeptide consisting of three structured domains, that is, C-terminal domain I (responsible for receptor binding),
domain II (responsible for oligomerization and membrane insertion), and domain III (which may participate in physical changes
when the CPE protein inserts into membranes). Native CPE binds to claudin receptors, which are components of the tight
junction. The bound toxin then assembles into a hexameric prepore on the membrane surface, prior to the insertion of this
oligomer into membranes to form an active pore. The toxin is especially lethal for cells expressing large amounts of claudin-
3 or -4, which includes many cancer cells. Initial studies suggest that native CPE has potential usefulness for treating several
cancers where claudin CPE receptors are overexpressed. However, some challenges with immunogenicity, toxicity, and (possibly)
the development of resistance may need to be overcome. An alternative approach now being explored is to utilize C-CPE, which
corresponds approximately to receptor binding domain I, to enhance paracellular permeability and delivery of chemotherapeutic
agents against cancer cells. Alternatively, C-CPE fusion proteins may prove superior to use of native CPE for cancer treatment.
Finally, C-CPE may have application for other medical treatments, including vaccination or increasing drug absorption. The
coming years should witness increasing exploitation of this otherwise formidable toxin.
1.IntroductiontoClostridium perfringens
Enterotoxin(CPE)
Clostridium perfringens is a major pathogen of humans
and livestock [1]. This Gram-positive anaerobe causes
both histotoxic infections, such as gas gangrene (clostridial
myonecrosis), and enteric infections, such as human food
poisoning. As typical amongst pathogenic clostridial spp.,
the virulence of C. perfringens is largely attributable to
its ability to produce an arsenal of potent protein toxins.
Production of four of these toxins (alpha, beta, epsilon, and
iota) is used to classify C. perfringens strains into one of ﬁve
types (A–E). Less than 5% of all C. perfringens type A isolates
produce another toxin named C. perfringens enterotoxin
(CPE) that is biomedically important, although not used
in the toxin typing classiﬁcation system [2]. After a brief
introduction to this unique toxin, promising eﬀorts to utilize
CPE, or its derivatives, for cancer therapy will be described
1.1. The Role of CPE in Natural Disease. CPE-producing C.
perfringens type A strains cause the second most common
bacterial food poisoning in the USA, as well as many cases
of human nonfoodborne gastrointestinal diseases, such as
antibiotic-associateddiarrhea[2].Thefoodpoisoning devel-
ops when foods contaminated with large numbers of CPE-
producing type A strains are ingested; the ingested bacteria
then brieﬂy grow in the small intestine before committing
to sporulation. It is during this in vivo sporulation that2 Journal of Toxicology
the enterotoxin is produced. Molecular Koch’s postulates
analyses have demonstrated that production of CPE is
essential for CPE-positive type A human food poisoning
or nonfoodborne gastrointestinal disease isolates to cause
gastrointestinal eﬀects in animal models [3].
Most, but not all, C. perfringens type A food poisoning
strainscarrytheirenterotoxingene(cpe)onthechromosome
[2]. In contrast, the cpe gene of type A nonfoodborne human
disease strains is located on large (∼70–75kb) plasmids [4].
Amongst cpe-positive type A strains there are two major
families of cpe plasmids [5]. These enterotoxin plasmids can
be conjugative [6], presumably due to the presence of a
Tn916-like region named tcp that has been experimentally
shown to mediate transfer of other C. perfringensconjugative
plasmids [7].
Expression of the cpe gene is regulated by sporulation-
associated alternative sigma factors [8, 9]. Speciﬁcally, one
alternative sigma factor (SigF) controls expression of two
other alternative sigma factors (SigK and SigE), which then
direct transcription of cpe mRNA from several SigK- or
SigE-dependent promoters located upstream of the cpe ORF.
Exceptionally large amounts of CPE can be produced during
sporulation; for example, CPE can represent 20% of total
protein in some sporulating CPE-positive C. perfringens type
A strains [2].
Once produced, CPE is not immediately secreted [2].
Instead it accumulates in the cytoplasm of the mother cell
until the completion of sporulation. When the mother cell
then lyses to release the mature spore, CPE is released into
the intestinal lumen, where it binds and acts as described in
the following section.
The in vivo outcome of natural CPE action during
gastrointestinal disease is desquamation of the intestinal
epithelium, intestinal necrosis, and the accumulation of
luminal ﬂuid [1]. These eﬀects account for the natural
gastrointestinal symptoms of CPE-associated disease, which
most commonly include diarrhea and abdominal cramps.
Typically,people aresickened with C.perfringenstypeAf ood
poisoning for 12–24 hours and then recover. However, this
illness can be fatal in the elderly or in people suﬀering from
medication-induced constipation [10].
1.2. The Cellular Action of CPE. As shown in Figure 1, the
current model of CPE action begins with binding of this
toxin to claudin receptors (described in detail below). This
binding results in formation of a small (∼90kDa) SDS-
sensitive complex. Besides CPE, the small complex also
contains [11] both claudin receptors and claudins incapable
of binding CPE (i.e., nonreceptor claudins). Presumably
the presence of nonreceptor claudins in small complex
is attributable to claudin: claudin interactions. Six small
complexes are then thought to oligomerize into an SDS-
resistant large complex named CPE hexamer-1, or CH-1.
This hypothesis is based upon results of heteromer gel shift
analyses, which identiﬁed the presence of six CPE molecules
in each CH-1 complex [11]. CH-1 is ∼450kDa in size and
contains, in addition to six CPE molecules, both receptor
and nonreceptor claudins [11]. CH-1 initially assembles as
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Figure 1: Model for CPE-induced cytotoxicity. CPE ﬁrst binds to
claudin receptors to form an ∼90kDa small complex. Six small
complexes are then thought to oligomerize on the membrane
surface to form a CH-1 prepore. The prepore then inserts into
membranes to form the active pore. This results in entry of calcium
into cells, which activates calpain. When a high CPE dose is used,
there is substantial entry of calcium into cells, causing a strong
calpain activation; this results in cell death by oncosis. Lower CPE
doses cause more limited calcium inﬂux and thus a milder calpain
activation; these cells die by classical caspase 3-mediated apoptosis.
a prepore on the membrane surface; however, at 37◦C this
prepore then rapidly inserts into membranes to form an
active pore [12].
Formation of the CH-1 pore results in calcium inﬂux,
which (via calpain activation) leads to cell death [13, 14].
At moderate CPE doses, where modest CPE pore formation
allows only limited calcium inﬂux, CPE-treated cells die
from a classical caspase 3-mediated apoptosis. At higher CPE
doses, where large amounts of CPE pore formation results in
a massive calcium inﬂux, cells die from oncosis.
CPE pore formation also leads to morphologic damage
that exposes the basolateral surface of cells. This allows
formation of a second bigger (∼650kDa) large complex
named CH-2 [15]. In addition to six copies of CPE and
both receptor and nonreceptor claudins, CH-2 also contains
another tight junction protein named occludin [11, 15].
Formation of CH-2 leads to internalization of occludin into
the cytoplasm [11]; claudins are also internalized inside
native CPE-treated cells although it is not clear if this is due
toCH-1formation,CH-2formation,ortoformationofboth
complexes. These eﬀects likely help to explain the observed
ability of native CPE to disrupt tight junctions [16].
2. The CPE Structure/FunctionRelationship
2.1. Cytotoxicity Domains of CPE. CPE consists of a 319
amino acid polypeptide (Mr 35,317) with a unique primary
sequence [2]. The CPE structure/function relationship has
been extensively analyzed by combined genetic, biochemical,
and structural biology approaches (Figure 2). As this review
was being prepared, the structure of the native CPE has
just been reported [18]. This structure revealed that CPE isJournal of Toxicology 3
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Figure 2: CPE structure versus function relationship. Panel A shows the functional regions of CPE, including the unstructured N-terminal
sequences comprising amino acids 1–37 (black box), the domain II sequences mediating oligomerization and membrane insertion (white
boxes), the domain III sequences that may participate when CPE inserts into membranes (green boxes), and the domain I sequences that
mediateCPEreceptorbinding(bluebox).ShownbelowthedrawingisthestructureofdomainI(usedwithpermissionfrom[17]),including
three tyrosine residues that interact with claudin receptors. Panel B shows the predicted structure of claudins. The amino acids in the turn
region of extracellular loop 2are shown to the right of claudin, with thetwo residues (Nand, to a lesser extent, L) important for CPEbinding
highlighted in red.
a three-domain protein, reminiscent of several other pore-
forming toxins.
The N-terminal 37 amino acids of native CPE lack a
deﬁnable structure and are not necessary for toxicity [2].
In fact, removing these amino acids by chymotrypsin, as
may occur in the intestines during disease, produces a 2–3-
foldmorepotent toxin [2].Thisproteolytic activationoccurs
because removal of the N-terminal CPE sequences exposes
the CPE region between amino acids 47 to 51, which reside
in domain II, to promote CH-1 formation. Thus, this CPE
region apparently functions as a latch that facilitates CPE
oligomerization. Site-directed mutagenesis studies showed
that particularly important domain II residues for CH-1
formation are (i) the Asp at CPE residue 48 and (ii) the Ile
at CPE residue 51 [19].
CPE domain II also contains a region spanning from
residues 81 to 106 that appears to be a transmembrane stem
[12]. Removal of these residues produces a CPE variant that
can form CH-1 but is unable to kill cells or form pores. This
eﬀect is consistent with CPE residues 81 to 106 mediating
the insertion of this transmembrane stem into membranes.
Membrane insertion of all six transmembrane stems, from
the six CPE proteins present in CH-1, resultsin β-barrel pore
formation.
Domain III may undergo structural changes during the
prepore to pore transition that facilitate insertion of the
CPEtransmembranestemintolipidbilayers,facilitatingpore
formation [18].
2.2. Receptor-Binding Domain of CPE. Over 20 years ago it
was shown that a recombinant CPE fragment corresponding
to the C-terminal half of the native toxin retains full
receptor-binding activity [2]. However, (as expected from
the preceding section) this C-terminal CPE fragment named
C-CPE was nontoxic since it lacks the N-terminal regions
necessary for CH-1 formation and insertion of CH-1 into
membranes to form a pore. Deletion mutagenesis and
synthetic peptide approaches later localized [2]m o s tC P E
receptor-binding activity to the 30 C-terminal amino acids
(Figure 2). More recently, site-directed mutagenesis studies
demonstrated that three Tyr residues, located at positions
306, 310, and 312 of the native toxin protein are important
for receptor binding [21].
C-CPE (residues 194 to 319 of the native toxin) approx-
imately corresponds to domain I of the native CPE protein
[17, 18]. Domain I consists of a nine beta strand sandwich
that shares structural similarity with the receptor binding
domains of some other bacterial toxins, including the large
CryfamilyofBacillusthuringiensistoxins[17].Bycorrelating
this C-CPE structure with the previous binding-activity
mapping studies described above, it is apparent that the
receptor-binding site of CPE resides on a large loop located
between beta strands 8 and 9.
3.ClaudinsasCPEReceptors
3.1.IntroductiontotheClaudins. Mammaliantightjunctions
act as both fences and gates, that is, they represent important
barriers for an epithelium and also regulate paracellular
permeability [22]. Studies conducted over the past 15 years
have determined that the tight junction is comprised of
several proteins, the most important of which are the
claudins [22]. The claudins are a 24-member family of4 Journal of Toxicology
∼20–25kDa proteins that are predicted to consist of four
transmembrane domains, two extracellular loops (ECL-1
andECL-2),andacytoplasmictailthatcanmediatesignaling
cascades. Claudins polymerize into strands that comprise
much of the tight junction. The distribution of individual
claudins varies amongst diﬀerent tissues. As described in
detail later, claudins are also overexpressed in many cancers.
3.2. Evidence that CPE Binds to Claudin Receptors
3.2.1. Fibroblast Transfectant Studies. In 1997, Katahira et
al. reported that when ﬁbroblasts, which are naturally CPE-
resistant, were transfected to express an ∼22kDa Vero cell
protein, they gained CPE sensitivity [23]. The Vero cell
protein expressed by these transfectants had properties of a
CPE receptor since the ﬁbroblast transfectants acquired the
ability to bind signiﬁcant levels of the toxin and to form
high molecular weight complexes that are now recognized
as CH-1. This Vero cell CPE receptor protein was later
identiﬁed as claudin-4. It was also determined [24] that,
at physiologic concentrations, the enterotoxin can bind to
transfected ﬁbroblasts expressing claudin-3, -4, -6, -8, or
-14. However, no CPE binding was detected to transfectants
expressing claudins-1, -2, -5, or -10.
3.2.2. Studies with Naturally CPE-Sensitive Enterocyte-Like
Cells. A more recent study by Robertson et al. demonstrated
that CPE also interacts with claudins in naturally CPE-
sensitive Caco-2 cells, which are a human enterocyte-like cell
line [11]. Using coimmunoprecipitation and electroelution
approaches, this study showed both the CPE small complex
and CH-1 large complex formed in Caco-2 cells can contain,
in addition to CPE, receptor claudins-3 and -4, along with
the nonreceptor claudin-1. In addition to CPE, receptor
claudins, and nonreceptor claudins, the CH-2 complex
formed in Caco-2 cells also contains occludin [15]. The
stoichiometry of claudins in CH-1 and CH-2, or occludin in
CH-2, has not yet been determined.
3.3. Mapping of the CPE Binding Site in Claudin Receptors.
The structure of a claudin has not been solved at the time
w h e nt h i sr e v i e wi sb e i n gp r e p a r e d .H o w e v e r ,a sm e n t i o n e d
earlier (and depicted in Figure 2), claudins are predicted
to possess two extracellular loops named ECL-1 and ECL-
2. An early study using claudin chimeras consisting of the
N-terminal half of CPE receptor claudin-4 fused with the
C-terminal half of CPE nonreceptor claudin-1 suggested
that CPE interacts with the putative ECL-2 region [24].
This hypothesis was rigorously conﬁrmed by a recent study
[25] using more speciﬁc chimeric claudins, which showed
that substituting only the predicted ECL-2 sequence of
claudin-4 into a claudin-1 backbone is suﬃcient to produce
ﬁbroblast transfectants that are very sensitive to CPE. The
reverse was also true, that is, transfectants expressing a
chimeric claudin, where only the claudin-1 ECL-2 had been
speciﬁcally substituted into the claudin-4 backbone, were
CPE-insensitive.
Several recent studies (reviewed in [26]) have focused
on understanding the speciﬁc ECL-2 residues of claudin
receptors that mediate CPE binding. These studies have uti-
lized a variety of approaches including arrays of immobilized
ECL-2 synthetic peptides, solubilized claudins, or transfec-
tants expressing claudin mutant. Results from these studies
suggested that ECL-2 possesses a helix-turn-helix motif that
interacts with CPE. An Asn residue in the middle of this turn
appears to be important for CPE binding; some evidence
suggeststhataLeuresiduelocatedtworesiduesfromthisAsn
may also participate in the binding of this toxin.
4. CPE andCancer Treatment
4.1. Introduction. Since approximately 85% of malignant
tumors are derived from epithelial cells, an epithelium-
targeted therapeutic strategy has been the focus of cancer
translational research. As mentioned earlier, claudins are
the major components of paracellular tight junctions (TJs),
distribute at the most apical junctions between epithelial
cells, and play an essential role in the control of paracellular
transport. Furthermore, Claudin-3 and -4 have been identi-
ﬁed as the speciﬁc receptors for CPE, which is of potential
therapeutic signiﬁcance since these two claudins are abun-
dantly expressed in ovarian, breast, uterine, and pancreatic
cancers [27]. While CPE can trigger lysis of epithelial cells by
binding to claudin-3 and claudin-4, with resultant initiation
of massive permeability changes, osmotic cell ballooning,
and cytolysis within 5–15min (see previous sections of
this review), cells lacking expression of the CPE receptors
are completely unaﬀected by this enterotoxin [19]. These
observations have raised the possibility that CPE may be an
innovative claudin-targeted therapy for malignant tumors.
In fact, eﬀorts have been made to use CPE in the treatment
of claudin-overexpressing cancers during the past few years.
4.2. CPE Treatment and Ovarian Cancer. Ovarian cancer re-
mains the most lethal gynecologic malignancy in the Uni-
ted States. Approximately 90% of patients with advanced-
stage ovarian cancer develop recurrence and inevitably
die from the development of chemotherapy resistance.
Therefore, the discovery of novel and eﬀective therapy is
of immediate clinical importance. Previous studies have
demonstrated that claudin-3 and -4 were among the six
most diﬀerentially upregulated genes in ovarian cancer cells,
but their expression is undetectable in normal ovaries. Of
particular note, chemotherapy-resistant/recurrent ovarian
cancers express claudin-3 and -4 at signiﬁcantly higher levels
than chemotherapy-sensitive cancers [28].
These overexpressed claudins may represent promising
targets for the use of CPE as a tumor-targeting therapy
against this aggressive disease. Indeed, Santin and colleagues
successfully used CPE to treat an animal model of chemo-
therapy-resistant human ovarian cancer [29]. They found
that all ovarian cancer cells, regardless of their resistance to
chemotherapeutic agents, showed a dose-dependent cyto-
toxic response and died rapidly after 24 hours of exposure
to CPE. Furthermore, in this animal model employingJournal of Toxicology 5
chemotherapy-resistant human ovarian cancer xenografts,
multipleintraperitoneal(i.p.)sublethaldosesofCPEranging
f r o m5t o8 . 5 μg/mL signiﬁcantly inhibited tumor growth
and extended the survival of mice harboring a large tumor
burden of chemotherapy-resistant ovarian cancer. The appli-
cation was well tolerated throughout the treatment period.
Therefore, CPE-based therapy may have potential as a novel
treatment for chemotherapy-resistant ovarian cancer.
4.3. CPE Treatment and Breast Cancer. Breast cancer is
one of the most common malignancies worldwide. Despite
tamoxifen and aromatase inhibitor having signiﬁcantly im-
proved long-term survival of patients diagnosed at the early
stages, advanced breast cancer and metastatic breast cancer
are still incurable diseases. Claudin-3 and claudin-4 are over-
expressed in most primary breast carcinomas and breast
cancer brain metastases but undetectable in normal breast
epithelial cells. In 2004, Kominsky et al. reported [30]f o r
the ﬁrst time that intratumoral CPE treatment of T47D
h u m a nb r e a s tc a n c e rc e l lx e n o g r a f t sr e s u l t e di ns i g n i ﬁ c a n t
tumor suppression and necrosis in SCID mice without any
side eﬀects. However, i.p. administration of the same dose
of CPE was toxic and had no eﬀect on tumor volume. CPE
also damaged breast cancer cell lines in a claudin-dependent
manner but did not aﬀect cell lines lacking claudin-3 and -4
[30].
In later studies [20], those investigators found that
intracranial administration of CPE retarded tumor growth
andincreasedsurvivalintwomurinemodelsofbreastcancer
brain metastasis without any apparent systematic or CNS
toxicity (Figure 3). These two studies suggest that the local
administration of CPE may be useful in the treatment of
breast cancer.
Overexpression of claudin-3 and -4 has been found in
uterine serous papillary carcinoma (USPC) and correlates
with a more aggressive phenotype and a worse prognosis. A
study by Santin et al. has demonstrated that CPE eﬀectively
and speciﬁcally triggers cytolysis of primary and metastatic
USPC cell lines in a dose-dependent manner whereas nor-
mal cells lacking claudin-3 and -4 are unaﬀected by CPE
treatment [31]. In particular, multiple intratumoral injec-
tions of CPE in large subcutaneous USPC xenografts led
to tumor necrosis and even tumor disappearance in 100%
of animals. Similarly, i.p. injection of sublethal doses of
CPE signiﬁcantly suppressed tumor growth and extended
survival of animals harboring chemotherapy-resistant intra-
abdominal USPC.The local/regional administrations of CPE
were well tolerated without observable adverse events in
animals.
4.4. CPE Treatment of Pancreatic and Prostate Cancers. CPE
has also been used to treat pancreatic and prostate cancers in
nude mice or in vitro by diﬀerent research groups. Michl et
al.reportedthatintratumoralinjectionsofCPEinpancreatic
cancer xenografts resulted in apparent tumor suppression
and necrosis in mice, and that CPE treatment also caused
anacutedose-dependentcytotoxiceﬀectinpancreaticcancer
cells in vitro [32]. In prostate cancer, Long et al. showed that
the prostate cancer metastatic cells from the bone marrow
were sensitive to CPE-mediated cytolysis in vitro [33]. These
two preclinical studies suggest that CPE may have potential
as a novel therapy for primary and metastatic malignancies
expressing claudin-3 and -4.
4.5. Challenges of Using Native CPE for Cancer Therapy.
Although the speciﬁcity and rapidity of CPE-mediated cyto-
lysismayincreaseanticancereﬃcacyandreduceopportunity
for the development of drug resistance, its clinical appli-
cation encounters some challenges. Since claudin-3 and -
4 are expressed in some normal tissues such as prostate,
lung, and the gastrointestinal tract, systemic toxicity is an
important concern for CPE therapy. In this context, many
investigators have chosen the local administration of native
CPE to treat cancers. This approach, however, does not
appear to be a good option for some metastatic cancers such
as lung metastasis or multiple metastases. Moreover, some
adverse events have sometimes been observed even following
the local administration of CPE during several studies [30,
34]. Furthermore, CPE is recognized as a virulence factor
responsible for the pathophysiological responses associated
with a common food poisoning, proinﬂammatory cytokine
response and other human diseases [34]. Another potential
problem would include possible immune responses against
CPE. Since CPE-associated foodborne illness is so common,
many people already have serum antibodies against this
toxin. It is unclear whether these serum CPE antibodies
include neutralizing antibodies but CPE does contain at least
one neutralizing epitope, present in the CPE binding domain
[2]. Other challenges include determining optimal dosage
and regimen, development of drug resistance, and long-term
safety concerns. Therefore, further detailed studies will be
required to resolve these issues.
5. C-CPE andCancer Treatment
Although the clinical application of CPE is limited by
its potentially signiﬁcant toxic side eﬀects, the C-terminal
binding domain of CPE (C-CPE) overcomes this drawback
of CPE and has recently emerged as a promising cancer
therapeutic agent due to its unique properties. For example,
C-CPE can disrupt the paracellular TJ barrier by binding
to claudin-3 and -4 in the epithelia and thus improve drug
delivery in a noncytotoxic fashion. It also has a smaller
molecular size that might provide less immunogenicity than
CPE.
The paracellular TJs are the primary barrier to the trans-
port of solutes from the apical surface to the core of cells.
Agent uptake via the paracellular pathway in the epithe-lia is
considered an attractive route for the absorption of chemo-
therapies. Given that claudin-3 and -4 are overexpressed in
several cancers and are major components of cell TJs, their
downregulation by C-CPE may prove a novel strategy for
enhancingconventionalchemotherapydeliveryintoclaudin-
positive cancer cells [36].
Ourgrouprecentlyinvestigatedtheeﬃcacyofacombina-
tion therapy using a chemotherapeutic agent with C-CPE as6 Journal of Toxicology
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Figure 3: Eﬃcacy of CPE in the treatment of breast cancer brain metastasis. (a, b) Brain tumors were established in mice using the human
breast cancer cell line MDA-MB-468 and the murine breast cancer cell line NT2.5-luc. Tumors were treated by intracranial administration of
0.5μg CPE versus PBS on days 5, 7, and 9. (c, d) For the NT2.5-luc brain tumor model, noninvasive bioluminescent imaging was done twice
per week beginning on day 4. Bioluminescent images from ﬁve representative mice are shown for each experimental group at day 19 (c).
Photonﬂuxwasmeasuredovertheindicatedtimecourseasanindicationoftumorgrowth(d).Diﬀerences insurvivalbetween experimental
groups were analyzed using the log-rank test. Reproduced with permission from [20].
compared to the single-agent chemotherapeutic agent [35].
Using three-dimensional and monolayer culture models
and a xenograft mouse model of human EOC cells, we
found that C-CPE enhanced the chemosensitivities of EOC
cell lines to Taxol or Carboplatin at low concentrations
in a claudin-dependent fashion. Moreover, repeated i.p.
administration of C-CPE in combination with Taxol signif-
icantly suppressed large tumor burdens by about 59%
compared with control or Taxol alone and showed no
apparent toxic drawback of CPE as encountered in previous
studies (Figure 4). Our study suggests that, at relatively low
concentrations, C-CPE may enhance the sensitivity of EOC
cells and other claudin-sensitive tumor cells to conventional
chemotherapy and thus alleviate systemic side eﬀects of
the agents.
Indeed, C-CPE could be useful not only as an anticancer
drug enhancer but also as a carrier to deliver a variety of
toxins leading to a spectrum of new anticancer drugs of high
selectivity. TNF-α has been demonstrated to be an attractive
antitumor agent in a variety of animal models but clinical
application has been limited due to its failure to concentrate
at the site of tumors and the development of severe side
eﬀects. To solve the problem, Yuan et al. engineered a C-
CPE-TNF fusion toxin that was >6.7-fold more cytotoxicJournal of Toxicology 7
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Figure 4: Combination therapy of C-CPE and taxol attenuates EOC xenograft growth in vivo. Female SCID mice were inoculated s.c.
with 5 × 106 SKOV-3 cells. Four weeks later, the mice harboring large tumor burden were intraperitoneally administered with taxol alone
(20mg/kg), taxol combined with C-CPE (0.1mg/kg), or vehicle (PBS) twice a week for 4 weeks. (a) Growth curves of tumors were presented
as the mean volume normalized to the start volume. ∗The combination of C-CPE and taxol led to a signiﬁcant tumor suppression compared
with vehicle or taxol alone (P<0.05). (b) After 4 weeks of treatment, immunostaining of Ki67 and TUNEL was performed to evaluate cell
proliferation and apoptosis in EOC xenografts.
∗P < 0.05;
∗∗P < 0.001. Reproduced with permission from [35].
than free TNF to ovarian cancer cells expressing claudin-
3 and -4; whereas the TNF component in the fusion was
5-fold less potent than free TNF, suggesting that C-CPE-
TNF fusion may prevent or decrease the systemic side
eﬀects caused by TNF [37]. Besides ovarian cancer, Saeki
et al. fused C-CPE to the protein synthesis inhibitory fac-
tor (PSIF) derived from Pseudomonas aeruginosa exotoxin
A for breast cancer that expresses high levels of claudin-
3 and -4 [38]. The C-CPE-PSIF fusion selectively damaged
claudin-expressing breast cancer cell lines, and repeated
intratumoral injections signiﬁcantly suppressed tumor size
by 36% without causing apparent side eﬀects in mice [38].
These two studies indicate that C-CPE may be a useful
carrierfordeliveringtoxinstoclaudin-sensitivemalignancies8 Journal of Toxicology
with higher anticancer potency and less systemic side
eﬀects.
The advantages of this claudin-targeted C-CPE-based
cancer therapy are signiﬁcant: tumor-targeted therapy, less
immune response, and an improved therapeutic potency not
achieved with previous treatments. There remain challenges
t ob eo v e r c o m e ,h o w e v e r ,b e f o r ew ec a ns e ea n ym a j o rm e d i -
cal advances in treating cancer with C-CPE: (1) determining
safedosagesandschedules,(2)choosingoptimaladministra-
tion routes, (3) avoiding potential immunogenicity, and (4)
improvingeﬀectivenessforpreventingand/ortreatingcancer
metastases. Therefore, further studies and clinical trials are
required to determine whether C-CPE could be developed as
a claudin-targeted novel therapeutic agent for the treatment
of cancer.
6. Use of C-CPE for Other MedicalApplications
In addition to cancer treatment, C-CPE has been utilized to
treat other medical conditions. For example, with the inten-
tion of developing a potent mucosal vaccination approach, a
nasal vaccine of C-CPE-fused antigen has been prepared and
applied in mice without mucosal injury and side eﬀects [39].
In addition, the ability of C-CPE to enhance paracellular
permeability has been exploited by using this protein to
increase drug absorption from the intestines [40]. One
potential issue regarding the use of C-CPE for increasing
intestinal drug absorption could be possible gastrointestinal
side eﬀects such as diarrhea, due to increased paracellular
permeability. However, C-CPE does not increase luminal
ﬂuid levels in rabbit ileal loops, possibly arguing against this
concern [41].
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